Skip to main content
OpenTrials
Completed

NCT Number: NCT06346522

Gabapentin Versus Trospium Chloride for Prevention of a Catheter-related Bladder Discomfort Inside the ICU

Catheter-related bladder discomfort (CRBD) is a frequent complaint after urinary bladder catheterization which is commonly done in the perioperative period. CRBD shows similar symptoms to overactive bladder (OAB); so, drugs used for the management of OAB could influence symptoms of CRBD. Trospium chloride and gabapentin are effective in managing patient with OAB even the resistant cases. We will evaluate and compare the efficacy of both oral trospium and gabapentin on prevention of CRBD in the postoperative period in the ICU in in patients undergoing spinal surgery and requiring intraoperative catheterization of the urinary bladder.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Ain Shams University-Faculty of Medicine

Cairo, Egypt

About this study

  • Study will be conducted in the intensive care units (ICU) of Ain Shams University Hospitals, Cairo, Egypt
  • After satisfactory pain control and full recovery in the postanesthesia care unit (PACU), the patient will be transferred to the ICU as a case of postoperative care after elective spinal diskectomy surgeries (cervical, dorsal or lumber) with removal of the damaged portion of the herniated or degenerated disks. Admission to ICU will be for medical, surgical or anesthesia related causes.
  • Standard monitoring devices via GE monitor will be connected to the patient as electrocardiogram (ECG) for heart rate (beats/min), pulse oximetry for (SPO2 as a percentage) and non-invasive blood pressure (NIBP) (mmHg).Temperature of the patient in Celsius (◦C), random blood sugar (mg/dl) and urine output (ml/hour) will be monitored also. Follow-up by standard postoperative laboratory tests will be done too.
  • After the patient will regain feeding according to the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines [1],the consented and enrolled 120 patients will be randomly assigned to one of the following groups and oral drug will be taken with sips of water:
  • Group G (40 patients): Gabapentin (GaptinR) 400mg oral capsule
  • Group T (40 patients): Trospium chloride slow release (TrospikanR SR) 60mg oral capsule
  • Group C (40 patients): Non-pharmacological standard of care control group who administered nothing
  • Incidence and severity of CRBD will be assessed by 4-point severity scale developed by Agarwal in1,2,6,12,24 hours after the study drugs intake . Assessment of pain severity and control will be done by using Numerical Pain Rating Scale (NPRS) and measuring total fentanyl requirements in the 1st 24h in micrograms (µg/day). Side effects of the study drugs will be recorded and managed accordingly with the use of Ramsay sedation score to assess sedation level one hour after the study drugs intake .
  • Patients will continue their monitored care in the ICU till the control of the causes of their ICU admission or their end.
  • Demographic data, causes for postoperative care in the ICU (Medical, surgical or anesthesia related) and spine surgery site and number for each (cervical, dorsal, lumber) will be collected and recorded.The collected study data results will be revised, electronically recorded in datasheet, coded, tabulated, analyzed, and processed using the proper computerized statistical package program. Suitable statistical analysis will be done according to the type of data obtained for each parameter with comparison between groups to identify any significant differences between them

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Both males and females with age 20-65 years
  • American Society of Anesthesiologists (ASA) physical status class I, II or III.
  • Patients will undergoing elective spinal surgery and will require catheterization of the urinary bladder.

Exclusion criteria

  • known allergy to the study drugs or patient refusal.
  • Urinary bladder pathology as overactive bladder (frequency more than 3 times in the night or more than 8 times in 24 h), bladder outflow obstruction, urinary tract infection or malignancy
  • Preoperative neurological bladder and/or bowel involvement secondary to spinal cord compression.
  • Chronic opioids use for chronic pain, drugs or alcohol abuse
  • Moderate to severe hepatic disease, renal impairment with creatinine clearance (CrCl) less than 30 ml/minute
  • Narrow angle glaucoma
  • Psychiatric diseases
  • Gastrointestinal obstructive conditions as severe chronic constipation or ileus

Treatment and study plan

Gabapentin (Gaptin ®) 400mg oral capsule once

Drug

After the patient will regain feeding, the patients will take with sips of water Gabapentin (Gaptin ®) 400mg oral capsule once in the first 24 hour after icu admission

Other names: Gaptin ®

Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule

Drug

After the patient will regain feeding, the patients will take with sips of water Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule once in the first 24 hour after icu admission

Other names: Trospikan ® SR

Primary outcomes

  1. The incidence (yes/no) and severity of catheter-related bladder discomfort (CRBD) in 1,2,6,12,24 hours after the study drugs intake

    Time frame: First 24 hours after the study drugs intake

    Severity of CRBD will be assessed and recorded by a CRBD 4-point severity scale developed by Agarwal et al as following:

    • No discomfort
    • Mild: urinary urgency or suprapubic discomfort reported by the patient on questioning only
    • Moderate: urinary urgency or suprapubic discomfort reported by the patient themselves without being questioned and not accompanied by behavioral changes
    • Severe: urinary urgency or suprapubic discomfort reported by the patient themselves and accompanied by behavioral changes such as attempts to remove the catheter, verbal responses, and restless movements of extremities) [2]

Secondary outcomes

  1. Total fentanyl requirements in micrograms (µg)

    Time frame: First 24 hours after the study drugs intake

    Total fentanyl requirements in the 1st 24h after study drugs intake in micrograms (µg/day)

  2. Numerical Pain Rating Scale (NPRS) (0-10)

    Time frame: First 24 hours after the study drugs intake

    NPRS for measurement of surgical pain intensity. It consists of a 10 cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').NPRS will be assessed at 1,2,6,12,24 hours after the study drugs intake.

  3. Side effects of the study drugs

    Time frame: First 24 hours after the study drugs intake

    They includes:

    • Nausea and vomiting
    • Dry mouth
    • Light headedness or confusion
    • Headache
    • Tachycardia
    • Blurred vision
    • Facial flushing
    • Agitation
    • Constipation
  4. Ramsay sedation score

    Time frame: After one hour of the study drugs intake

    Ramsay sedation score [3].It will be assessed after one hour of the study drugs intake

    Score Sedation level

    • Awake; agitated or restless or both
    • Awake; cooperative, oriented, and tranquil
    • Awake but responds to commands only
    • Asleep; brisk response to light glabellar tap or loud auditory stimulus
    • Asleep; sluggish response to light glabellar tap or loud auditory stimulus
    • Asleep; no response to glabellar tap or loud auditory stimulus

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Efficacy of Gabapentin Versus Trospium Chloride for Prevention of Catheter-related Bladder Discomfort (CRBD) Inside the Intensive Care Unit (ICU): a Prospective, Randomized,Comparative Clinical Study

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Apr 4, 2024
Registry last updated
Jul 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.